

# Environmental Risk Assessment Data Summary

<u>Active Pharmaceutical Ingredient</u>	<u>Medical Product</u>
Ranitidine	Zantac

## Executive Summary

GSK is committed to ensuring that our compounds do not adversely affect the environment. We carry out state of the art environmental testing on our pharmaceuticals and use these data in risk assessments to evaluate potential for harm to the environment. We post summaries of our Environmental Risk Assessments on the GSK website as part of our commitment to data transparency.

**This Environmental Risk Assessment (ERA) has been conducted for Ranitidine and demonstrates that the use of this drug substance is considered to result in insignificant environmental risk. This evaluation is based on the Predicted Environmental Concentration (PEC) to Predicted No Effects Concentration (PNEC) ratio of less than 0.1. Ranitidine is an active ingredient in GSK pharmaceutical products and pharmaceutical products sold by other companies. This assessment takes account of the total quantity of active ingredient marketed by GSK and all other companies.**

**The following pages contain the technical background information.**

## Technical Background Information

### Environmental Fate

Ranitidine is not readily nor inherently biodegradable and is not susceptible to hydrolysis. It is expected to persist in the environment. However, moderate removal of ranitidine is expected to occur in wastewater treatment plants via primary biodegradation and sorption to sludge solids. This substance is water soluble, and a low partition coefficient suggests it is unlikely to bioconcentrate in exposed aquatic organisms.

### PEC/PNEC Risk Quotient Calculation

The PEC/PNEC risk quotient calculation is the standard quantitative method of risk assessment and is approved by major national and international regulatory agencies [2, 3, 4].

### **Predicted Environmental Concentration (PEC)**

The PEC has been calculated based on the following data:

$$\text{PEC } (\mu\text{g/L}) = \frac{A \times 1\text{E} + 09 \times (100 - R)}{365 \times P \times V \times D \times 100}$$

where:

A (kg/year) = total use of Ranitidine based on patient consumption in the European Union and UK in 2021 (IQVIA Data).

R (%) = removal rate due to loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation. For Ranitidine it has been assumed that R = 0% as a worst-case scenario [3].

P = Population of European Union + UK. Per capita use of drug substance A/P = 1.96E-05 kg/inhabitant (IQVIA Data).

V (L/day) = volume of wastewater per capita and day = 200, EMA default [2].

D = factor for dilution of wastewater by surface water flow = 10, EMA default [2].

*NB: PEC, conservatively, is based on no metabolism and no removal of drug substance to sludge solids. It is assumed that 100% of drug substance enters the aquatic environment.*

**PEC = 0.027  $\mu\text{g/L}$**

## Predicted No Effects Concentration (PNEC)

PNEC ( $\mu\text{g/L}$ ) = lowest NOEC/50, where 50 is the assessment factor applied for two long-term NOECs [2, 3]. The NOEC for water flea (= 310  $\mu\text{g/L}$ ) has been used for this calculation since it is the most sensitive of the species tested.

$$\text{PNEC} = 310/50 = 6.20 \mu\text{g/L}$$

## PEC/PNEC Risk Characterisation

$$\text{PEC/PNEC} = 0.027/6.20$$

$$\text{PEC/PNEC} = 0.0044$$

The PEC/PNEC is  $\leq 0.1$  which means the use of Ranitidine is considered to result in insignificant environmental risk, in accordance with the Fass environmental classification scheme [4].

All relevant environmental fate and ecotoxicity data are published in Section 12 of the Material Safety Data Sheet (MSDS) for the medical product. The MSDS is publicly available at <http://www.msds-gsk.com/ExtMSDSlist.asp>.

## Metabolism and Excretion

Ranitidine is not extensively metabolised. The fraction of the dose recovered as metabolites is similar after both oral and i.v. dosing; and includes 6% of the dose in urine as the N-oxide, 2% as the S-oxide, 2% as desmethyranitidine and 1 to 2% as the furoic acid analogue. Plasma concentrations decline bi-exponentially, with a terminal half-life of 2-3 hours. The major route of elimination is renal. After IV administration of 150 mg 3H-ranitidine, 98% of the dose was recovered, including 5% in faeces and 93% in urine, of which 70% was unchanged parent drug. After oral administration of 150 mg 3H-ranitidine, 96% of the dose was recovered, 26% in faeces and 70% in urine of which 35% was unchanged parent drug. Less than 3% of the dose is excreted in bile. Renal clearance is approximately 500 mL/min, which exceeds glomerular filtration indicating net renal tubular secretion [1].

## References

1. Summary of Product Characteristics Zantac (ranitidine hydrochloride) 150mg tablets. GlaxoSmithKline, March 2014. <http://www.medicines.org.uk/EMC/>

2. Committee for Medicinal Products for Human Use (CHMP); Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. 1 June 2006, Ref EMEA/CPMP/SWP/4447/00.

[https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-risk-assessment-medicinal-products-human-use-first-version\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-risk-assessment-medicinal-products-human-use-first-version_en.pdf)

3. European Chemicals Agency (ECHA). 2008 Guidance on information requirements and chemical safety assessment.

[http://guidance.echa.europa.eu/docs/guidance\\_document/information\\_requirements\\_en.htm](http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_en.htm)

4. Fass Environmental Classification of Pharmaceuticals. 2012 v3.0 Guidance for Pharmaceutical Companies. [www.fass.se](http://www.fass.se)